Creating a multi-targeted medication that can simultaneously hinder both the androgen receptor variants and glucocorticoid receptor action holds the potential to overcome drug resistance, extend the duration of treatment efficacy, and ultimately enhance the therapeutic outcomes for prostate cancer patients. This evidence concerns the gene AR and prostate carcinoma.